FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR

In this study, we aimed to uncover the...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research

Related Links:

The objective of this study is to investigate current trends of skin cancer mortality in Germany. Data of the death statistics from 1998 to 2017 were analyzed using joinpoint regression models. Age standardized skin cancer mortality declined since 2013 (annual percentage change -2.1% [95% CI: -4.0 to -0.2%]), while in previous years an increase of +3.4% (95% CI: 1.3 to 5.4%) was observed. The development is mainly driven by a decreasing melanoma mortality. Possible causes of the trend change are especially the nationwide skin cancer screening which was introduced in 2008 and the growing availability of new system...
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
ConclusionsImmune checkpoint inhibition can trigger inflammation in virtually any organ in the body, leading to diverse clinical manifestations. To our knowledge, this is the first case report of eosinophilic enteritis due to ipilimumab plus nivolumab.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsAnalysis of the spatially constrained distribution of CD8+ and CD163+ cells, representative of the opposite circuits of antitumor vs protumor immunity, respectively, may assist in identifying melanoma patients with improved response and better outcome upon treatment with MAPK inhibitors. These data underline the role of endogenous immune microenvironment in predisposing metastatic melanoma patients to benefit from therapies targeting driver-oncogenic pathways.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
AbstractAlthough immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15 –60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit from ICIs is a major research focus for the oncology community. Thus far, predictive biomarker research has focused on tumor signatures such as microsatellite instability, programmed death-ligand 1 (PD-L1) expression and tumor mutational burden; clinical biomarkers have been far less studied. One potential clinical b...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ng Luo Wei-Dong Pan Twenty-seven L-shaped ortho-quinone analogs were designed and synthesized using a one pot double-radical synthetic strategy followed by removing methyl at C-3 of the furan ring and introducing a diverse side chain at C-2 of the furan ring. The synthetic derivatives were investigated for their cytotoxicity activities against human leukemia cells K562, prostate cancer cells PC3, and melanoma cells WM9. Compounds TB1, TB3, TB4, TB6, TC1, TC3, TC5, TC9, TC11, TC12, TC14, TC15, TC16, and TC17 exhibited a better broad-spectrum cytotoxicity on three cancer cells. TB7 and TC7 selectively displayed potent ...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma, adoptive cell immunotherapy for NSCLC, and...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Chemerin is a multifunctional protein acting mainly through the G protein-coupled receptor ChemR23/CMKLR1/Chemerin1. Its expression is frequently downregulated in human tumors, including in melanoma and squamous cell carcinoma of the skin and anti-tumoral properties of chemerin were reported in mouse tumor graft models. In the present study, we report the development of spontaneous skin tumors in aged ChemR23-deficient mice. In order to test the potential therapeutic benefit of chemerin analogs, a transgenic model in which bioactive chemerin is over-expressed by basal keratinocytes was generated. These animals are characte...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study does not provide evidence for an increased skin cancer risk in patients treated with NB-UVB phototherapy. However, we have detected the occurence of 10 cases of solar lentigines. Still, definitive prospective longitudinal studies with a greater number of patients and prolonged follow-up are required to specifically address skin cancer risk in relation to NB-UVB phototherapy.
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
Publication date: November 2019Source: Journal of Comparative Pathology, Volume 173Author(s): T.H.M. Vargas, L.H. Pulz, D.G. Ferro, R.A. Sobral, M.A.F.A. Venturini, H.L. Corrêa, R.F. StrefezziSummaryMalignant melanomas (MMs) represent 7% of all malignant neoplasms in dogs. Oral melanocytic neoplasms are often malignant and associated with poor prognosis. There are no universally accepted prognostic markers for canine oral melanoma. Galectin (Gal)-3 is a prognostic marker for human neoplasms such as thyroid, gastric, colorectal and prostate cancers. The protein is related to processes that favour cancer progression, s...
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
(Natural News) Taking care of your gut may be one of the ways that you can keep the threat of cancer at bay. A study published in the journal Nature Communications found that gut bacteria can enhance the ability of the immune system to fight cancers, particularly melanoma. The study was a collaboration involving over...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Melanoma | Skin Cancer | Study